UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.707

Sortiert nach

Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective

Clinical pharmacokinetics, 2016-09, Vol.55 (9), p.1045-1058

2016

Volltextzugriff (PDF)

Safety and Pharmacokinetics of Multiple 750-Milligram Doses of Intravenous Levofloxacin in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2001-07, Vol.45 (7), p.2122-2125

2001

Volltextzugriff (PDF)

Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis

Clinical pharmacokinetics, 2018, Vol.57 (1), p.71-85

2018

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis

Journal of clinical pharmacology, 2018-06, Vol.58 (6), p.717-726

2018

Volltextzugriff (PDF)

Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis

Clinical pharmacokinetics, 2011-12, Vol.50 (12), p.793-807

2011

Volltextzugriff (PDF)

The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics

The AAPS journal, 2013-01, Vol.15 (1), p.172-182

2013

Volltextzugriff (PDF)

Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure

Journal of clinical pharmacology, 2015-11, Vol.55 (11), p.1236-1247

2015

Volltextzugriff (PDF)

The Utility of a Population Approach in Drug–Drug Interaction Assessments: A Simulation Evaluation

Journal of clinical pharmacology, 2017-10, Vol.57 (10), p.1268-1278

2017

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim in Animals

Pharmaceutical research, 2013-03, Vol.30 (3), p.655-669

2013

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours

Clinical pharmacokinetics, 2012-04, Vol.51 (4), p.247-260

2012

Volltextzugriff (PDF)

Population cell life span models for effects of drugs following indirect mechanisms of action

Journal of pharmacokinetics and pharmacodynamics, 2005-12, Vol.32 (5-6), p.767-793

2005

Volltextzugriff (PDF)

Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects

The AAPS journal, 2010-12, Vol.12 (4), p.729-740

2010

Volltextzugriff (PDF)

Levofloxacin Population Pharmacokinetics and Creation of a Demographic Model for Prediction of Individual Drug Clearance in Patients with Serious Community-Acquired Infection

Antimicrobial Agents and Chemotherapy, 1998-05, Vol.42 (5), p.1098-1104

1998

Volltextzugriff (PDF)

Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors

Clinical cancer research, 2012-05, Vol.18 (9), p.2648-2657

2012

Volltextzugriff (PDF)

Double-Blind Evaluation of the Safety and Pharmacokinetics of Multiple Oral Once-Daily 750-Milligram and 1-Gram Doses of Levofloxacin in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 1998-04, Vol.42 (4), p.885-888

1998

Volltextzugriff (PDF)

Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions

Journal of clinical pharmacology, 2014-05, Vol.54 (5), p.593-601

2014

Volltextzugriff (PDF)

Therapeutic Protein Drug–Drug Interactions: Navigating the Knowledge Gaps–Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop

The AAPS journal, 2013-10, Vol.15 (4), p.933-940

2013

Volltextzugriff (PDF)

The clinical pharmacokinetics of levofloxacin

Clinical pharmacokinetics, 1997-02, Vol.32 (2), p.101-119

1997

Volltextzugriff (PDF)

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

JAMA : the journal of the American Medical Association, 1998-01, Vol.279 (2), p.125

1998

Volltextzugriff (PDF)

Pharmacokinetics and Safety of High-Dose and Extended-Interval Regimens of Levofloxacin in Human Immunodeficiency Virus-Infected Patients

Antimicrobial Agents and Chemotherapy, 1999-09, Vol.43 (9), p.2323-2327

1999

Volltextzugriff (PDF)

Development of Biosimilars-Pharmacokinetic and Pharmacodynamic Considerations

Journal of biopharmaceutical statistics, 2010-01, Vol.20 (1), p.46-61

2010

Volltextzugriff (PDF)

Single-Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen-Activated Protein Kinase Inhibitor: A First-in-Human Study

Journal of clinical pharmacology, 2003-04, Vol.43 (4), p.406-413

2003

Volltextzugriff (PDF)

The effect of epoetin dose on hematocrit

Kidney international, 2008-09, Vol.74 (6), p.827-827

2008

Volltextzugriff (PDF)

Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions: The Journal of Clinical Pharmacology

Journal of clinical pharmacology, 2014-05, Vol.54 (5), p.593-601

2014

Volltextzugriff (PDF)

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

The New England journal of medicine, 2013-07, Vol.369 (4), p.307-318

2013

Volltextzugriff (PDF)

1 – 25 von 1.707

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.417)
Mit Volltextzugriff
(1.523)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.703)
Japanisch
(170)
Chinesisch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Time
(138)
Journal Of Clinical Oncology
(37)
Cancer Research
(30)
Blood
(27)
The New England Journal Of Medicine
(19)
Plos One
(16)
Circulation
(15)
Journal Of The American College Of Cardiology
(15)
The Journal Of Urology
(13)
Jacc. Cardiovascular Imaging
(12)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective

Safety and Pharmacokinetics of Multiple 750-Milligram Doses of Intravenous Levofloxacin in Healthy Volunteers

Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis

Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis

Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis

The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics

Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure

The Utility of a Population Approach in Drug–Drug Interaction Assessments: A Simulation Evaluation

Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim in Animals

Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours

Population cell life span models for effects of drugs following indirect mechanisms of action

Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects

Levofloxacin Population Pharmacokinetics and Creation of a Demographic Model for Prediction of Individual Drug Clearance in Patients with Serious Community-Acquired Infection

Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors

Double-Blind Evaluation of the Safety and Pharmacokinetics of Multiple Oral Once-Daily 750-Milligram and 1-Gram Doses of Levofloxacin in Healthy Volunteers

Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions

Therapeutic Protein Drug–Drug Interactions: Navigating the Knowledge Gaps–Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop

The clinical pharmacokinetics of levofloxacin

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

Pharmacokinetics and Safety of High-Dose and Extended-Interval Regimens of Levofloxacin in Human Immunodeficiency Virus-Infected Patients

Development of Biosimilars-Pharmacokinetic and Pharmacodynamic Considerations

Single-Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen-Activated Protein Kinase Inhibitor: A First-in-Human Study

The effect of epoetin dose on hematocrit

Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions: The Journal of Clinical Pharmacology

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

Suchergebnisse filtern